b
r
c
r
c
l
e
n
f
human
cytomegaloviru
hcmv
infect
associ
sever
morbid
mortal
immunocompromis
individu
mainli
transplant
recipi
aid
patient
frequent
caus
congenit
malform
newborn
children
date
drug
licens
treatment
hcmv
infect
target
viral
dna
polymeras
suffer
mani
drawback
includ
longterm
toxic
low
potenc
poor
bioavail
addit
emerg
drugresist
viral
strain
becom
increas
problem
diseas
manag
final
none
current
antihcmv
drug
approv
treatment
congenit
infect
reason
still
strong
need
new
antihcmv
drug
novel
mechan
action
first
event
viru
replic
cycl
includ
attach
entri
immediateearli
gene
express
immediateearli
functionsin
particular
immediateearli
proteinrepres
attract
target
develop
novel
antivir
compound
inhibitor
would
block
express
viral
immediateearli
protein
play
key
role
pathogenesi
hcmv
infect
also
host
immunomodul
chang
cell
physiolog
induc
first
event
viru
infect
review
describ
current
knowledg
initi
phase
hcmv
replic
valid
potenti
novel
antivir
target
develop
compound
block
process
human
cytomegaloviru
hcmv
envelop
doublestrand
dna
viru
includ
herpesvirida
famili
basi
virion
structur
kinet
viral
gene
express
lifelong
persist
host
landolfo
et
al
mocarski
et
al
britt
strict
speci
specif
human
salivari
gland
tropism
slow
growth
cell
cultur
make
hcmv
prototyp
member
betaherpesviru
subfamili
hcmv
genom
consist
linear
doublestrand
dna
largest
among
herpesvirus
contain
icosahedr
protein
capsid
surround
proteinac
layer
term
tegument
turn
structur
enclos
lipid
bilay
call
envelop
matur
virion
particl
nm
diamet
larg
number
viral
encod
envelop
glycoprotein
expos
virion
surfac
whose
primari
function
mediat
viru
attach
entri
host
cell
penetr
cytoplasm
genom
migrat
nucleu
undergo
process
gene
express
replic
product
infect
hcmv
gene
express
tempor
coordin
regul
cascad
transcript
event
lead
synthesi
three
class
viral
protein
design
immediateearli
ie
earli
e
late
l
transcript
l
gene
occur
genom
replic
hcmv
gene
transcript
genom
replic
catalyz
cellular
rna
polymeras
ii
viral
dna
polymeras
respect
latter
enzym
target
licens
antihcmv
drug
hcmv
import
opportunist
pathogen
respons
signific
morbid
mortal
suscept
individu
like
immatur
immunocompromis
immun
system
date
vaccin
avail
prevent
hcmv
infect
drug
licens
manag
hcmv
diseas
recent
year
mani
research
group
focus
effort
exploit
altern
target
prophylaxi
therapi
hcmv
infect
new
hcmv
inhibitor
identifi
review
examin
earli
event
hcmv
replic
target
develop
novel
antihcmv
therapi
process
hcmv
attach
entri
ie
gene
express
describ
special
emphasi
place
molecul
inhibit
process
discuss
mechan
action
therapeut
potenti
drawback
hcmv
infect
occur
geograph
locat
socioeconom
group
although
high
popul
densiti
low
sanitari
condit
increas
risk
infect
cannon
et
al
hcmv
transmit
via
saliva
sexual
activ
placent
transfer
breastfeed
blood
transfus
solid
organ
hematopoiet
stem
cell
transplant
primari
infect
hcmv
establish
lifelong
latent
infect
period
reactiv
shed
infecti
viru
bodi
fluid
ie
urin
saliva
tear
milk
semen
cervic
secret
month
year
healthi
individu
hcmv
infect
effici
control
host
immun
respons
usual
run
asymptomat
except
case
mononucleosislik
syndrom
rare
complic
primari
hcmv
infect
immunocompet
individu
includ
arthralgia
arthriti
ulcer
coliti
pneumon
hepat
asept
mening
myocard
gandhi
khanna
contrast
hcmv
respons
sever
morbid
mortal
immunocompromis
individu
like
untreat
acquir
immunodefici
syndrom
aid
transplant
recipi
receiv
immunosuppress
agent
retin
primari
manifest
hcmv
infect
aid
patient
low
tcell
count
transplant
recipi
great
risk
develop
pneumonia
gastrointestin
diseas
suffer
acut
graft
reject
gandhi
khanna
steining
et
al
buyck
et
al
addit
hcmv
common
caus
congenit
infect
hcmvseroneg
pregnant
women
hcmv
transmit
mother
fetu
approxim
case
infect
newborn
manifest
symptom
birth
first
year
life
includ
birth
defect
development
disabl
microcephali
hear
loss
vision
loss
mental
retard
dollard
et
al
kenneson
cannon
final
larg
bodi
evid
link
hcmv
infect
acceler
number
vascular
diseas
atherosclerosi
restenosi
transplant
vascular
sclerosi
promot
chronic
allograft
reject
streblow
et
al
three
major
therapeut
approach
current
employ
manag
hcmv
infect
diseas
prophylact
therapi
without
evid
viru
replic
preemptiv
therapeut
suppress
viru
replic
absenc
diseas
treatment
establish
diseas
singh
snydman
date
antivir
drug
develop
employ
either
prophylact
preemptiv
therapi
direct
treatment
hcmv
diseas
five
compound
current
licens
treat
establish
hcmv
infect
ganciclovir
gcv
oral
prodrug
valganciclovir
vgcv
foscarnet
fo
cidofovir
cdv
fomivirsen
highdos
acyclovir
acv
recent
valaciclovir
vacv
also
use
prophylaxi
hcmv
transplant
recipi
recommend
treatment
activ
hcmv
diseas
antivir
agent
approv
yet
treatment
congenit
hcmv
infect
except
fomivirsen
antisens
oligonucleotid
direct
hcmv
major
immediateearli
mie
gene
locu
see
section
descript
fomivirsen
compound
target
either
directli
indirectli
viral
dna
polymeras
yeh
coen
ganciclovir
guanin
fig
first
antivir
agent
approv
treatment
hcmv
infect
remain
firstlin
choic
treatment
hcmv
diseas
markham
fauld
razon
emeri
gcv
acycl
nucleosid
analog
prodrug
hcmvinfect
cell
gcv
undergo
first
step
phosphoryl
viral
protein
kinas
convert
cellular
kinas
activ
triphosph
form
gcvtp
littler
et
al
sullivan
et
al
gcvtp
interact
catalyt
subunit
viral
dna
polymeras
inhibit
dna
synthesi
compet
natur
nucleosid
triphosph
dgtp
act
chain
termin
gcv
inhibit
viral
polymeras
potent
cellular
dna
polymeras
mutat
confer
resist
gcv
map
dna
polymeras
protein
kinas
gene
mutat
associ
resist
gcv
gener
map
conserv
subdomain
confer
crossresist
cdv
less
commonli
fo
gilbert
boivin
introduct
highli
activ
antiretrovir
therapi
emerg
resist
strain
major
concern
aid
patient
receiv
prolong
mainten
therapi
eric
et
al
lurain
et
al
baldanti
et
al
baldanti
et
al
current
drugresist
still
repres
import
problem
transplant
recipi
lurain
chou
side
effect
gcv
includ
hematolog
abnorm
primarili
neutropenia
anemia
thrombocytopenia
base
preclin
toxicolog
studi
probabl
longterm
reproduct
toxic
fauld
heel
markham
fauld
gcv
current
avail
intraven
formul
cytoven
roch
sustainedreleas
intraocular
implant
baush
lomb
approv
treatment
hcmv
retin
gcv
oral
formul
mg
capsul
roch
receiv
approv
treatment
hcmv
retin
mainten
therapi
although
oral
formul
repres
import
advanc
treatment
option
mainten
prophylact
therapi
low
bioavail
approxim
high
pill
burden
ti
three
time
day
regimen
pose
sever
limit
fact
oral
gcv
longer
market
circumv
low
oral
bioavail
gcv
prodrugvalganciclovir
roch
fig
develop
vgcv
lvalyl
ester
gcv
oral
bioavail
around
rapidli
metabol
activ
form
ie
gcv
intestin
wall
liver
valganciclovir
approv
treatment
hcmv
retin
aid
patient
cvetkov
wellington
later
prophylact
treatment
hcmv
solid
organ
transplant
recipi
vgcv
replac
oral
gcv
clinic
practic
foscarnet
fig
second
drug
approv
treatment
hcmv
retin
aid
patient
sinc
fo
pyrophosph
analog
inhibit
viral
dna
polymeras
chrisp
clissold
wagstaff
bryson
differ
gcv
cdv
requir
prior
activ
virusencod
cellular
enzym
bind
pyrophosph
bind
site
block
cleavag
pyrophosph
group
termin
nucleosid
triphosph
ad
grow
dna
chain
point
mutat
confer
resist
fo
map
gene
moreov
crossresist
observ
gcv
fo
sever
laboratori
clinic
isol
fo
avail
astrazeneca
trisodium
salt
phosphonoform
acid
administ
intraven
fo
consid
secondlin
therapi
howev
drug
choic
patient
fail
gcv
therapi
due
viral
resist
treat
gcv
due
doselimit
neutropenia
leucopenia
razon
emeri
due
potenti
nephrotox
administr
requir
slow
infus
extens
prehydr
frequent
monitor
serum
creatinin
level
naesen
de
clercq
cidofovir
cytosin
fig
acycl
nucleosid
phosphon
analog
dcmp
mechan
action
similar
gcv
acycl
nucleosid
phosphon
depend
activ
virusencod
enzym
activ
convert
cellular
kinas
diphosphoryl
form
act
inhibitor
viral
dna
polymeras
caus
prematur
chain
termin
viral
dna
synthesi
de
clercq
holi
cdv
approv
treatment
hcmv
retin
aid
patient
cdv
avail
intraven
formul
gilead
oral
bioavail
low
less
one
advantag
compar
gcv
fo
long
intracellular
halflif
aduma
et
al
good
efficaci
achiev
infrequ
dose
major
limit
cdv
sever
renal
toxic
lead
electrolyt
imbal
lea
bryson
fact
requir
coadministr
probenecid
prehydrat
reduc
nephrotox
effect
neutropenia
anoth
sideeffect
associ
cdv
also
shown
carcinogen
teratogen
preclin
toxicolog
studi
lea
bryson
reason
cdv
remain
secondlin
therapi
potenti
cdv
prodrug
avoid
renal
tubular
uptak
concentr
evalu
final
acyclovir
guanin
fig
analo
like
gcv
acv
prodrug
phosphoryl
subsequ
cellular
kinas
triphosph
form
activ
form
promot
chain
termin
grow
viral
dna
acv
less
effici
substrat
gcv
addit
acvtp
display
shorter
halflif
compar
gcvtp
infect
cell
result
lower
intracellular
level
activ
drug
probabl
reason
acv
exhibit
lower
vitro
potenc
compar
gcv
hcmvinfect
cell
like
gcv
drug
resist
aris
mutat
gene
valaciclovir
glaxosmithklin
fig
lvalyl
ester
acv
lowanc
et
al
present
higher
bioavail
compar
oral
acv
perri
fauld
acv
vacv
lack
suffici
potenc
use
treatment
activ
hcmv
diseas
primari
use
transplant
patient
suppress
hsv
reactiv
prophylact
treatment
drug
also
reduc
occurr
hcmv
infect
diseas
solid
organ
transplant
recipi
particular
vacv
approv
sever
countri
prophylaxi
hcmv
infect
renal
heart
transplant
recipi
current
avail
antihcmv
drug
sever
drawback
limit
clinic
util
villarr
compound
limit
oral
bioavail
thu
must
administ
intraven
addit
current
approv
system
drug
unfavor
safeti
profil
sever
acut
longterm
toxic
special
concern
pediatr
popul
longterm
reproduct
toxic
carcinogen
emerg
drugresist
viral
strain
also
pose
increas
problem
diseas
manag
sinc
approv
antihcmv
compound
share
similar
mechan
action
target
viral
dna
polymeras
mutant
virus
resist
one
drug
sometim
resist
other
although
rule
final
safeti
efficaci
current
avail
drug
treatment
congenit
hcmv
infect
still
subject
debat
despit
result
random
control
trial
see
exampl
kimberlin
et
al
thu
still
strong
need
identifi
new
target
antihcmv
chemotherapi
develop
novel
antivir
compound
treatment
strategi
initi
phase
hcmv
replic
cycl
might
provid
use
target
new
antivir
drug
inde
number
report
antivir
compound
inhibit
hcmv
replic
earli
stage
recent
publish
great
interest
rais
compel
notion
inhibit
hcmv
replic
initi
stage
eg
inhibit
viru
attach
entri
interf
express
andor
activ
ie
gene
product
could
benefici
one
level
particular
drug
target
attach
entri
would
especi
attract
drug
would
need
enter
cell
exert
activ
would
inhibit
synthesi
downstream
potenti
toxic
viral
protein
addit
although
cellfre
viru
transmiss
believ
unlik
hcmv
replic
highli
cellassoci
cellfre
viru
commonli
found
bodi
fluid
urin
saliva
breast
milk
often
high
titer
britt
thu
block
viru
attach
might
prevent
hcmv
transmiss
via
excret
reduc
dissemin
infect
sever
immunocompromis
patient
larg
amount
cellfre
infecti
viru
document
peripher
blood
britt
sever
compound
inhibit
attach
andor
entri
hcmv
identifi
see
section
rel
larg
charg
molecul
exemplifi
heparin
bind
certain
viral
glycoprotein
mediat
initi
attach
hcmv
heparan
sulfat
moieti
cell
surfac
kari
gehrz
two
particularli
desir
stage
inhibit
viral
replic
transcript
translat
event
lead
express
ie
protein
importantli
increas
evid
ie
protein
particular
concert
play
crucial
role
pathogenesi
hcmv
infect
induc
broad
dysregul
host
gene
express
lead
chang
host
cell
physiolog
contribut
hcmvinduc
cell
cycl
alter
immunomodul
proinflammatori
respons
stinski
petrik
current
avail
antihcmv
drug
target
viral
dna
polymeras
impact
effect
produc
earli
phase
thu
hcmv
dna
replic
inhibit
one
drug
ie
gene
product
accumul
infect
cell
caus
disturb
host
cell
function
import
ie
function
led
suggest
prevent
express
andor
function
may
provid
altern
strategi
inhibit
hcmv
reactiv
replic
immunopathogenesi
fomivirsen
market
antihcmv
drug
target
dna
polymeras
fact
potent
inhibit
express
protein
thu
prevent
hcmv
replic
effect
proinflammatori
immun
mechan
azad
et
al
anderson
et
al
perri
balfour
grillon
lanz
although
fomivirsen
limit
therapeut
applic
introduct
drug
clinic
use
provid
proofofconcept
inhibit
hcmv
replic
earli
stage
feasibl
antivir
strategi
novel
antihcmv
agent
block
ie
protein
express
activ
without
caus
major
advers
effect
may
exploit
treatment
patient
respond
current
use
inhibitor
viral
dna
replic
wide
spectrum
diseas
caus
hcmv
correl
remark
broad
organ
cell
tropism
landolfo
et
al
gerna
et
al
epitheli
cell
line
rhinopharinx
genit
tract
repres
two
major
portal
hcmv
entri
bodi
primari
infect
rout
transmiss
oral
sexual
respect
addit
endotheli
cell
vascular
tree
infect
blood
trasfus
dissemin
infect
revello
gerna
howev
hcmvinfect
individu
mani
cell
type
found
infect
besid
epitheli
endotheli
cell
includ
fibroblast
smooth
muscl
cell
stromal
cell
monocytesmacrophag
neutrophil
neuron
cell
hepatocyt
dankner
et
al
cinqu
et
al
van
den
pol
et
al
sinzger
et
al
vitro
sever
cell
type
permiss
hcmv
replic
although
high
cellfre
viru
yield
obtain
human
skin
human
embryon
lung
fibroblast
helf
human
umbil
vein
endotheli
cell
revello
et
al
hahn
et
al
gerna
et
al
note
howev
hcmv
abl
bind
fuse
initi
replic
almost
vertebr
cell
type
test
nowlin
et
al
ubiquit
distribut
hcmv
infect
wide
rang
suscept
cell
depend
least
part
presenc
broadli
express
receptor
cellspecif
receptor
may
act
combin
mediat
process
viru
attach
entri
hcmv
penetr
host
cell
complex
seri
event
begin
adsorpt
onto
heparan
sulfat
proteoglycan
hspg
process
concentr
viru
cell
surfac
compton
et
al
hspg
wide
express
surfac
almost
eukaryot
cell
type
typic
consist
core
protein
link
heparan
sulfat
hs
chain
hs
made
unbranch
anion
polysaccharid
compos
variabl
sulfat
repeat
disaccharid
unit
disaccharid
unit
occur
frequent
within
hs
compos
glucuron
acid
link
nacetylglucosamin
undergo
sever
modif
golgi
apparatu
includ
ndeacetyl
nsulfat
glucosamin
epimer
glucuron
acid
form
iduron
acid
residu
iduron
glucuron
acid
residu
well
glucosamin
residu
lindahl
et
al
lindahl
et
al
esko
lindahl
turnbul
et
al
gorsi
stringer
syndecan
glypican
two
type
cellsurfac
hspg
syndecan
famili
compris
transmembran
hspg
glypican
typic
glycosylphosphatidylinositol
gpi
anchor
hspg
fig
date
known
whether
hcmv
bind
syndecan
glypican
hcmv
attach
hspg
seem
primarli
mediat
glycoprotein
complex
gmgn
kari
gehrz
kari
fig
hcmv
attach
cell
surfac
hspg
posit
charg
region
viral
glycoprotein
complex
gmgn
interact
neg
charg
heparan
sulfat
chain
link
core
protein
process
concentr
viru
cell
surfac
syndecan
glypican
major
cellsurfac
hspg
syndecan
famili
compris
transmembran
hspg
glypican
typic
glycosylphosphatidylinositol
gpi
anchor
hspg
sinc
yet
elucid
whether
hcmv
adsorb
syndecan
glypican
molecul
shown
gehrz
hcmv
glycoprotein
gb
absolut
requir
viru
attach
isaacson
compton
despit
abil
bind
heparin
solubl
mimic
hspg
compton
et
al
compound
belong
class
exert
antivir
activ
prevent
hcmv
interact
hspg
although
addit
mechan
might
involv
case
one
type
inhibitor
consist
sulfat
polysaccharid
larg
group
charg
polym
mimic
hs
chain
compound
interact
viral
glycoprotein
thu
block
viru
attach
hspg
competit
inhibit
fig
second
type
inhibitor
name
peptidederivat
dendrim
act
opposit
mechan
bind
hspg
thu
capabl
compet
hcmv
attach
cell
surfac
fig
lactoferrin
compon
innat
immun
respons
antagon
hcmv
infect
least
part
bind
hspg
therefor
includ
section
clinic
potenti
inhibitor
yet
determin
sulfat
polysaccharid
polyanion
compound
interfer
electrostat
interact
neg
charg
sulfatedcarboxyl
group
hs
chain
expos
cell
surfac
posit
charg
region
hcmv
glycoprotein
ghosh
et
al
gener
rule
antivir
potenc
increas
augment
degre
sulfat
ie
number
sulfat
group
per
monosaccharid
residu
length
oligosaccharid
chain
witvrouw
de
clercq
former
featur
rais
likelihood
oligosaccharid
success
interact
hsbind
domain
viru
attach
protein
wherea
latter
enabl
singl
oligosaccharid
simultan
make
contact
multipl
copi
viru
attach
protein
well
induc
crosslink
virion
last
three
decad
mani
sulfat
polysaccharid
marin
alga
cyanobacteria
anim
sourc
shown
potent
antihcmv
activ
preclin
studi
addit
semisynthet
compound
also
inhibit
hcmv
attach
tabl
summar
sulfat
polysaccharid
endow
antihcmv
activ
potenc
accord
tabl
nostoflan
appear
activ
vitro
among
sulfat
polysaccharid
natur
origin
howev
must
note
direct
comparison
antivir
potenc
limit
valu
sinc
compound
test
differ
antivir
assay
experiment
set
latter
includ
cell
type
viru
strain
time
compound
addit
interestingli
addit
mechan
antivir
action
report
spirulanlik
polysaccharid
besid
inhibit
viru
attach
penetr
compound
seem
induc
intracellular
antivir
mechan
probabl
alter
membran
properti
cellular
signal
process
rechter
et
al
addit
effect
taken
account
assess
antivir
activ
sulfat
polysaccharid
may
interact
cell
surfac
induc
intracellular
signal
pathway
dextran
sulfat
pentosan
polysulf
bacteri
sulfat
glycosaminoglycan
chemic
degrad
heparin
semisynthet
compound
report
hcmv
inhibitor
sinc
earli
recent
new
class
semisynthet
polysaccharid
emerg
potent
inhibitor
viral
attach
ie
sulfat
deriv
e
coli
capsular
polysaccharid
activ
three
sexual
transmit
virus
name
human
immunodefici
viru
hiv
human
papillomaviru
herp
simplex
viru
promis
candid
ingredi
topic
microbicid
vicenzi
et
al
lembo
et
al
pinna
et
al
rusnati
et
al
capsular
polysaccharid
e
coli
structur
heparinh
biosynthet
precursor
nacetylheparosan
observ
repres
start
point
synthesi
deriv
chemic
enzymat
method
inde
addit
sulfat
group
oposit
sugar
led
synthesi
chemic
defin
compound
differ
degre
sulfat
charg
distribut
rusnati
et
al
unlik
heparin
sulfat
polysaccharid
devoid
anticoagul
activ
tailor
structur
molecular
weight
close
mimic
cell
surfac
hs
obtain
good
toxicolog
profil
recent
panel
deriv
test
hcmv
prove
activ
activ
compound
os
h
higli
sulfat
nand
oposit
abl
potent
inhibit
replic
laboratori
hcmv
strain
clinic
viral
isol
viru
strain
resist
antihcmv
drug
current
use
therapi
moreov
os
h
inhibit
celltocel
spread
viru
taken
group
sulfat
polysaccharid
emerg
broad
spectrum
antivir
compound
enter
clinic
trial
activ
ingredi
topic
microbicid
prevent
sexual
transmiss
hiv
rusnati
et
al
howev
appear
less
attract
treat
system
infect
like
sustain
hcmv
major
undesir
effect
associ
use
mani
sulfat
polysaccharid
vivo
anticoagul
activ
howev
number
compound
minim
effect
plasma
coagul
could
select
includ
fucoidan
galactan
spirulan
xylomannan
heteroglycan
deriv
hayashi
et
al
chattopadhyay
et
al
mandal
et
al
chattopadhyay
et
al
among
fucoidan
spirulan
deriv
activ
hcmv
tabl
anoth
factor
limit
use
sulfat
polysaccharid
vivo
poor
bioavail
flexner
et
al
although
adsorb
oral
administr
ghosh
et
al
sulfat
polysaccharid
show
antihcmv
activ
human
semisynthet
compound
curdlan
sulfat
potent
antihiv
inhibitor
vitro
gordon
et
al
intraven
toler
studi
hivand
hcmvinfect
individu
patient
test
hcmvneg
end
day
curdlan
sulfat
well
toler
gordon
et
al
peptidederivat
dendrim
two
peptidederivat
dendrim
name
recent
report
potent
inhibitor
hcmv
attach
luganini
et
al
consist
lysin
peptidyl
branch
core
four
coval
attach
surfac
peptid
function
unit
contain
cluster
basic
amino
acid
bind
neg
charg
sulfat
carboxyl
group
hs
inde
deriv
ctermin
glutamin
residu
function
aslrvrikkq
group
remov
could
bind
heparin
immobil
biacor
sensor
chip
cellfre
model
resembl
interact
cell
surfac
hs
donalisio
et
al
moreov
bind
cell
surfac
prevent
solubl
heparin
well
pretreat
heparinas
heparitinas
luganini
et
al
indic
abil
dendrim
bind
cellular
hs
mode
action
allow
prevent
attach
sever
hcmv
strain
includ
gcvresist
clinic
isol
primari
fibroblast
endotheli
cell
inde
pretreat
helf
cell
produc
signific
inhibit
hcmv
replic
ec
respect
effect
neither
viru
strain
specif
cell
type
specif
sinc
also
observ
helf
infect
clinic
isol
ec
human
umbil
vein
endotheli
cell
infect
endotheliotrop
strain
ec
respect
use
peptidederivat
dendrim
hcmv
still
preclin
stage
develop
attract
molecul
due
small
size
nanometr
abil
display
multipl
copi
activ
surfac
group
multival
high
anti
hcmv
potenc
moreov
target
cellular
compon
emerg
hcmv
resist
strain
could
less
like
howev
possibl
drawback
mode
action
induct
undesir
cellular
signal
cascad
alter
cellular
respons
hs
interact
varieti
extracellular
ligand
particip
mani
event
cell
adhes
migrat
prolifer
differenti
perrimon
bernfield
tumova
et
al
issu
throughli
address
preclin
studi
candid
antivir
molecul
prevent
andor
control
hcmv
infect
lactoferrin
lactoferrin
lf
ironbind
globular
glycoprotein
molecular
mass
kda
vivo
produc
neutrophil
mammari
gland
lactat
mucos
epitheli
cell
iyer
lonnerd
bayn
bezwoda
lonnerd
iyer
therefor
lf
present
high
level
milk
colostrum
also
found
mucos
secret
bodi
fluid
includ
uterin
fluid
vagin
secret
semin
fluid
saliva
bile
pancreat
juic
small
intestin
secret
nasal
secret
tear
levay
viljoen
lonnerd
iyer
lf
exert
broad
antimicrobi
iyer
lonnerd
levay
viljoen
lonnerd
iyer
kuiper
et
al
antivir
activ
harmsen
et
al
marchetti
et
al
shimizu
et
al
swart
et
al
grover
et
al
van
der
strate
et
al
thu
consid
part
innat
defens
mainli
mucos
earli
studi
report
antihcmv
activ
intact
lf
bovin
human
milk
colostrum
serum
ec
valu
ml
bovin
lf
human
lf
viral
strain
harmsen
et
al
swart
et
al
subsequ
investig
confirm
find
viral
strain
obtain
ec
valu
somewhat
lower
determin
bovin
lf
human
lf
beljaar
et
al
studi
bovin
lf
potent
human
isoform
propos
activ
lf
occur
level
viru
attach
entri
sinc
preincub
target
cell
lf
essenti
protect
effect
decreas
lf
ad
infect
harmsen
et
al
beljaar
et
al
ntermin
portion
protein
call
lactoferricin
requir
antivir
activ
contain
stretch
posit
charg
amino
acid
bind
hspg
van
berkel
et
al
swart
et
al
andersen
et
al
moreov
addit
posit
charg
lf
amin
increas
antihcmv
effect
wherea
neg
charg
acyl
deriv
lf
devoid
activ
beljaar
et
al
final
preincub
lf
heparin
mutual
block
antivir
activ
andersen
et
al
taken
togeth
studi
demonstr
antihcmv
activ
lf
requir
specif
distribut
posit
neg
charg
within
molecul
suggest
least
part
antivir
activ
may
accomplish
prevent
viru
dock
onto
cell
surfac
hspg
entri
cell
howev
mechan
action
lf
hcmv
remain
fulli
elucid
fact
lf
one
antimicrobi
compon
breast
milk
breastfeed
highrisk
factor
postnat
transmiss
hcmv
led
research
hypothes
hcmv
could
inhibit
secret
contain
high
level
lf
therebi
prevent
transmiss
newborn
hypothesi
disprov
studi
demonstr
lf
concentr
breast
milk
correl
hcmv
transmiss
preterm
neonat
van
der
strate
et
al
van
der
strate
colleagu
demonstr
synergist
effect
bovin
lf
cdv
vitro
could
explain
inhibit
two
differ
step
hcmv
replic
van
der
strate
et
al
contrast
combin
acv
fo
result
antagon
wherea
neither
synergi
antagon
observ
lf
combin
gcv
although
mechan
interact
remain
elucid
combin
therapi
consist
lf
cdv
deserv
investig
vivo
antihcmv
activ
lf
studi
vivo
rat
cytomegaloviru
model
without
immun
suppress
beljaar
et
al
moder
antivir
effect
observ
might
explain
suboptim
dosag
regimen
lf
presenc
antibodi
lf
latter
factor
unlik
play
role
human
treat
human
lf
earlier
studi
demonstr
abil
lf
inhibit
murin
cytomegaloviru
replic
vivo
stimul
activ
natur
killer
cell
shimizu
et
al
contrast
studi
beljaar
colleagu
indic
contribut
immunomodulatori
activ
lf
overal
antivir
activ
less
import
compar
direct
inhibitori
effect
hcmv
attach
entri
beljaar
et
al
hcmv
entri
process
yet
fulli
understood
viru
attach
hspg
follow
stabl
interact
postattach
entri
receptor
trigger
signal
transduct
cascad
eventu
viru
entri
result
releas
virion
virion
compon
directli
cell
fig
epiderm
growth
factor
receptor
egfr
integrin
propos
hcmv
receptor
role
still
controversi
find
egfr
express
helf
cell
breast
carcinoma
cell
correl
suscept
cell
hcmv
infect
antiegfr
antibodi
block
hcmv
entri
helf
support
role
egfr
hcmv
entri
receptor
wang
et
al
moreov
recent
demonstr
inhibit
egfr
signal
abrog
hcmv
entri
monocyt
indic
egfr
serv
cellular
tropism
receptor
chan
et
al
howev
egfr
express
sever
hcmv
permiss
cell
type
studi
demonstr
requir
hcmv
entri
signal
cobb
et
al
isaacson
et
al
plateletderiv
growth
factor
rather
egfr
necessari
effici
viral
entri
soroceanu
et
al
integrin
also
identifi
cellular
receptor
hcmv
entri
feir
et
al
evid
support
role
integrin
entri
receptor
includ
identif
integrin
bind
disintegrinlik
domain
within
hcmv
gb
protein
physic
interact
domain
integrin
abil
solubl
form
domain
deriv
peptid
block
hcmv
infect
postattach
step
feir
et
al
feir
et
al
studi
support
role
egfr
integrin
entri
receptor
carri
infect
fibroblast
hcmv
laboratori
strain
strain
harbor
delet
mutat
rearrang
within
genom
area
compris
gene
import
determin
hcmv
tropism
endotheli
epitheli
cell
cha
et
al
murphi
et
al
dolan
et
al
hahn
et
al
wang
shenk
role
egfr
integrin
entri
receptor
confirm
epitheli
endotheli
cell
infect
viral
strain
endow
broader
cell
tropism
shown
hcmv
entri
epitheli
endotheli
cell
depend
complex
viral
protein
made
requir
endocytosi
low
phdepend
fusion
fig
wang
shenk
ryckman
et
al
ryckman
et
al
contrast
hcmv
entri
fibroblast
mediat
ghglgo
complex
involv
phindepend
fusion
viral
envelop
cell
plasma
membran
fig
compton
et
al
huber
compton
end
replic
cycl
viral
progeni
spread
directli
adjac
cell
cellular
contact
across
cellular
junction
mechan
call
celltocel
spread
johnson
huber
number
hcmv
protein
propos
contribut
celltocel
spread
includ
endotheli
cell
fibroblast
go
gb
fibroblast
jiang
et
al
isaacson
compton
effort
identifi
pharmacolog
agent
interfer
hcmv
entri
result
heterogen
group
compound
act
multipl
stage
entri
process
distinct
mechan
action
includ
natur
compound
like
dietari
polyphenol
small
molecul
synthet
peptid
oligonucleotid
neutral
antibodi
tabl
gener
entri
inhibitor
exert
biolog
properti
inhibit
proteinprotein
interact
prevent
membran
fusion
receptor
activ
still
earli
stage
develop
current
antihcmv
hyperimmun
globulin
prepar
licens
clinic
use
polyphenol
polyphenol
larg
group
antioxid
compound
mani
contain
fruit
veget
beverag
tea
coffe
beer
wine
fruit
drink
among
flavonoid
resveratrol
shown
inhibit
hcmv
replic
follow
stabl
interact
postattach
entri
receptor
trigger
intracellular
signal
cascad
hcmv
entri
epitheli
endotheli
cell
depend
viral
protein
requir
endocytosi
low
phdepend
fusion
hcmv
entri
fibroblast
mediat
ghglgo
complex
involv
phindepend
fusion
viral
envelop
plasma
membran
result
releas
capsid
tegument
protein
directli
cytoplasm
flavonoid
class
secondari
plant
metabolit
contain
carbon
atom
widespread
natur
fruit
tea
soybean
import
dietari
sourc
human
compound
possess
mark
antioxid
effect
heim
et
al
besid
properti
mani
report
propos
addit
biolog
activ
includ
antiinflammatori
antiprolif
vasculoprotect
antimicrobi
antivir
effect
formica
regelson
cushni
lamb
friedman
rathe
et
al
androutsopoulo
et
al
inde
differ
flavonoid
inhibit
replic
wide
array
virus
vitro
includ
hsv
polioviru
adenoviru
respiratori
syncyti
viru
sindbi
viru
parainfluenza
viru
pseudorabi
viru
rou
sarcoma
viru
sar
coronaviru
influenza
viru
hiv
amoro
et
al
hayashi
et
al
lin
et
al
mitrocotsa
et
al
robin
et
al
akula
et
al
chiang
et
al
wei
et
al
yi
et
al
co
et
al
observ
along
fact
variou
flavonoid
affect
cellular
signal
pathway
requir
hcmv
replic
eg
phosphatidyl
inositol
akt
mitogenactiv
protein
kinas
involv
stimul
search
flavonoid
endow
antihcmv
activ
studi
ever
et
al
identifi
nine
flavonoid
block
replic
hcmv
strain
town
among
baicalein
potent
inhibitor
ec
compound
origin
isol
root
scutellaria
baicalensi
herb
wide
use
chines
tradit
medicin
treatment
chronic
hepat
allergi
thrombot
stroke
inflammatori
diseas
shang
et
al
sever
studi
confirm
potent
antiinflammatori
effect
baicalein
sekiya
okuda
huang
et
al
chen
et
al
huang
et
al
far
antihcmv
activ
demonstr
baicalein
act
prior
ie
protein
express
primari
mechan
action
inhibit
hcmv
entri
block
egfr
tyrosin
kinas
activ
cellular
function
requir
hcmv
penetr
wang
et
al
chan
et
al
safeti
efficaci
issu
remain
address
vivo
see
also
next
section
resveratrol
resveratrol
natur
compound
produc
sever
plant
respons
bacteri
fungal
infect
stress
found
skin
red
grape
red
wine
plum
peanut
repres
primari
dietari
sourc
resveratrol
human
moreov
produc
chemic
synthesi
farina
et
al
engin
saccharomyc
cerevisia
tranta
et
al
mani
studi
report
benefici
effect
resveratrol
prevent
slow
progress
inflamm
cardiovascular
diseas
cancer
baur
sinclair
also
shown
resveratrol
inhibit
infect
sever
virus
vitro
includ
varicellazost
viru
sar
coronaviru
influenza
viru
docherti
et
al
palamara
et
al
docherti
et
al
li
et
al
moreov
activ
combin
therapi
hiv
heredia
et
al
vivo
studi
mice
show
topic
administr
resveratrol
inhibit
hsv
replic
vagina
limit
extravagin
diseas
docherti
et
al
docherti
et
al
antihcmv
activ
resveratrol
initi
document
confirm
screen
panel
stilben
relat
compound
atreid
et
al
ever
et
al
latter
studi
report
ec
resveratrol
hcmv
strain
town
select
index
least
stilben
stilbenelik
compound
examin
lack
antivir
activ
suggest
phenol
hydroxyl
group
resveratrol
requir
activ
investig
mode
action
reveal
resveratrol
act
within
first
h
infect
prevent
ie
gene
express
found
resveratrol
block
number
cellular
event
trigger
hcmv
earli
infect
ever
et
al
includ
egfr
phosphoryl
signal
activ
transcript
factor
nuclear
johnson
et
al
wang
et
al
light
find
author
propos
primari
mechan
action
resveratrol
hcmv
block
egfr
activ
thu
prevent
viru
entri
efficaci
resveratrol
antihcmv
agent
remain
investig
vivo
pharmacokinet
short
halflif
fact
extens
metabol
bodi
may
requir
high
intak
resveratrol
achiev
antivir
activ
baur
sinclair
like
anticanc
drug
eg
etoposid
doxorubicin
resveratrol
flavonoid
includ
baicalein
inhibit
activ
cellular
dna
topoisomeras
rais
concern
carcinogen
potenti
fetu
insuffici
detoxif
system
jo
et
al
leon
et
al
inde
high
intak
polyphenolflavonoid
compound
pregnanc
suspect
increas
risk
infant
earli
childhood
leukemia
caus
sitespecif
dna
cleavag
mll
gene
ross
strick
et
al
paolini
et
al
multipl
infect
moi
ec
hcmv
strain
determin
autom
assay
ec
yield
reduct
assay
moi
ec
increas
respect
addit
prevent
celltocel
spread
hcmv
cytotox
assay
cytotox
concentr
thu
select
index
interest
antivir
activ
specif
neither
hsv
varicellazost
viru
respiratori
syncyti
viru
close
relat
betaherpesvirus
murin
cmv
simian
cmv
rat
cmv
inhibit
mechanismofact
studi
reveal
act
within
first
h
hcmv
replic
cycl
remain
effect
ad
attach
prevent
cytoplasmtonucleu
transport
virion
viral
ie
e
gene
express
inhibitori
effect
revers
polyethylen
glycol
chemic
mediat
membran
fusion
moreov
mutant
virus
resist
bear
mutat
gb
suffici
confer
resist
taken
togeth
find
indic
prevent
hcmv
entri
inhibit
gbmediat
virion
envelop
fusion
cell
plasma
membran
although
develop
clinic
due
vivo
stabil
metabol
issu
discoveri
valid
gbmediat
virion
fusion
target
develop
new
antihcmv
strategi
enfuvirtid
clinic
use
encourag
ration
design
peptid
inhibitor
hcmv
entri
enfuvirtid
synthet
peptid
acid
correspond
ctermin
heptad
repeat
segment
hiv
fusion
protein
kilbi
et
al
heptad
repeat
motif
consist
sevenaminoacid
pattern
hydrophob
side
chain
occur
first
fourth
posit
structur
motif
basi
common
mode
helix
associ
protein
name
coiledcoil
lupa
heptad
repeat
motif
also
identifi
region
hcmv
gb
gh
glycoprotein
propos
play
role
hcmv
fusion
mechan
lopper
compton
support
hypothesi
demonstr
peptid
correspond
region
prevent
entri
varieti
clinic
laboratori
hcmv
strain
specif
manner
lopper
compton
find
valid
heptad
repeat
motif
target
develop
hcmv
entri
inhibitor
although
peptid
display
low
potenc
compar
enfuvirtid
thu
altern
strategi
explor
disrupt
coiledcoil
interact
promis
line
research
open
ration
develop
oligom
design
inhibit
gbmediat
hcmv
entri
english
et
al
peptid
display
secondari
structur
call
mimick
put
segment
within
gb
glycoprotein
identifi
highli
specif
inhibitor
hcmv
entri
probabl
act
alter
viral
fusion
machineri
english
et
al
intrins
advantag
respect
gbderiv
higher
antivir
potenc
resist
proteolyt
degrad
studi
howev
requir
determin
therapeut
potenti
phosphorothioatemodifi
oligonucleotid
cpg
oligodeoxynucleotid
odn
synthet
singlestrand
dna
fragment
contain
unmethyl
cytosineguanosin
cpg
dinucleotid
krieg
cpg
dinucleotid
rel
common
viral
bacteri
genom
recogn
pathogenassoci
molecular
pattern
tolllik
receptor
therefor
either
genom
contain
unmethyl
cpg
dinucleotid
cpg
odn
trigger
immunomodulatori
cascad
result
secret
varieti
proinflammatori
antivir
cytokin
activ
innat
adapt
immun
respons
properti
stimul
develop
cpg
odn
vaccin
adjuv
suggest
potenti
protect
viral
infect
nonspecif
manner
ashkar
et
al
dong
et
al
schlaepfer
et
al
wong
et
al
kamstrup
et
al
krieg
jiang
et
al
cpg
odn
belong
three
differ
class
ie
b
c
basi
distinct
structur
biolog
featur
recent
luganini
colleagu
report
prototyp
b
class
cpg
relat
odn
display
potent
select
antihcmv
activ
ec
hcmv
luganini
et
al
studi
mutant
version
cpg
reveal
activ
independ
presenc
cpg
dinucleotid
requir
phosphorothio
backbon
interestingli
cpg
exert
antivir
activ
block
viru
entri
mechan
involv
activ
tolllik
receptor
pathway
luganini
et
al
novel
mode
action
cpg
may
repres
start
point
develop
antihcmv
strategi
base
phosphorothioatemodifi
odn
importantli
number
studi
carri
rodent
human
reveal
good
safeti
profil
cpg
odn
krieg
hcmv
hyperimmun
globulin
human
monoclon
antibodi
passiv
immun
hcmv
hyperimmun
globulin
feasibl
strategi
prophylaxi
hcmv
infect
prevent
symptomat
hcmv
diseas
current
three
prepar
intraven
immunoglobulin
enrich
antibodi
hcmv
avail
market
cytogam
csl
behr
cytotect
biotest
ag
prepar
produc
australian
red
cross
blood
servic
product
contain
high
titer
neutral
antibodi
prevent
hcmv
entri
endotheli
epitheli
cell
cui
et
al
number
studi
clinic
trial
support
use
hcmv
hyperimmun
globulin
prophylaxi
hcmv
diseas
solid
organ
transplant
recipi
either
alon
combin
gcv
snydman
valantin
et
al
bonaro
et
al
contrast
use
hematolog
malign
hematopoiet
stem
cell
transplant
still
controversi
raanani
et
al
passiv
immun
cmv
hyperimmun
globulin
also
studi
utero
treatment
prevent
congenit
hcmv
infect
preclin
studi
base
mostli
guinea
pig
model
cytomegaloviru
infect
guinea
pig
cmv
cross
placenta
caus
infect
fetu
like
hcmv
human
moreov
guinea
pig
human
placenta
similar
schleiss
improv
perinat
outcom
treatment
congenit
guinea
pig
cmv
infect
observ
pave
way
clinic
trial
human
griffith
et
al
bratcher
et
al
administ
pregnant
women
primari
cmv
infect
hcmv
hyperimmun
globulin
shown
promis
result
treatment
prevent
fetal
infect
adler
nigro
howev
random
blind
control
trial
need
assess
benefit
passiv
immun
hcmv
hyperimmun
globulin
hcmv
congenit
infect
major
drawback
immunotherapi
base
hyperimmun
globulin
need
administ
high
dose
intraven
order
reach
therapeut
concentr
neutral
antibodi
least
part
consequ
low
potenc
observ
vitro
roy
grundi
safeti
intraven
immunoglobulin
purifi
blood
deriv
administ
safe
human
decad
nevertheless
risk
transmiss
infecti
agent
includ
virus
prion
complet
elimin
overcom
limit
improv
therapeut
potenti
passiv
immun
hcmv
two
group
recent
gener
human
monoclon
antibodi
mab
potent
neutral
hcmv
infect
vitro
funaro
et
al
macagno
et
al
group
util
immort
b
cell
hcmvimmun
donor
sourc
antibodi
immunoglobulin
produc
b
cell
expect
highli
relev
bodi
defens
hcmv
therefor
provid
favor
start
point
gener
highli
protect
mab
funaro
colleagu
develop
innov
technolog
exploit
gener
panel
mab
neutral
hcmv
infect
fibroblast
endotheli
cell
potenc
higher
commerci
avail
hcmv
hyperimmun
globulin
funaro
et
al
activ
mab
show
strong
bind
gb
gh
viral
glycoprotein
vh
vl
variabl
region
promis
candid
mab
clone
sequenc
use
gener
recombin
igg
display
neutral
activ
similar
parent
mab
macagno
colleagu
abl
gener
extrem
potent
mab
neutral
hcmv
infect
endotheli
epitheli
myeloid
cell
ec
valu
low
pm
rang
macagno
et
al
bind
conform
epitop
made
complex
conclus
human
natur
recombin
mab
promis
candid
passiv
immunotherapi
endow
higher
potenc
hyperimmun
immunoglobulin
devoid
risk
unwant
transmiss
infecti
pathogen
associ
use
plasma
deriv
moreov
expect
avoid
side
effect
human
mous
mab
includ
immunogen
rapid
remov
blood
system
inflammatori
effect
section
postentri
event
occur
hcmv
replic
dna
synthesi
summar
fig
describ
event
follow
hcmv
entri
still
poorli
character
despit
fact
known
yet
tegument
disassembl
evid
stage
protein
viral
tegument
play
major
role
guid
transport
viral
capsid
cytoplasm
cell
nucleu
subsequ
intranuclear
transloc
viral
genom
tegument
protein
like
involv
genomecontain
capsid
transport
nucleu
perhap
current
knowledg
activ
protein
well
recent
experiment
data
obtain
studi
herpesvirus
support
model
hcmv
postfus
event
clearli
illustr
kalejta
entri
hcmv
exploit
cellular
microtubul
network
travel
cell
membran
case
entri
via
fusion
fibroblast
endocyt
vesicl
case
entri
via
receptormedi
endocytosi
epithelialendotheli
cell
nucleu
viral
tegument
protein
complex
form
protein
involv
transport
viral
capsid
nuclear
membran
bechtel
shenk
howev
definit
cellular
bind
partner
identifi
yet
recent
studi
report
plusminu
direct
microtubul
motor
bind
viral
capsid
use
differ
tegument
protein
includ
also
hcmv
ortholog
radtk
et
al
furthermor
disrupt
cellular
microtubul
network
caus
drug
nocodazol
prevent
viral
ie
gene
express
ogawagoto
et
al
thu
highlight
potenti
process
target
novel
antivir
drug
viral
capsid
reach
nuclear
viral
tegument
protein
like
mayb
engag
transport
viru
capsid
cytoplasm
intranuclear
transloc
viral
genom
via
nuclear
pore
tegument
protein
abl
local
autonom
nucleu
intranuclear
deliveri
hcmv
genom
quickli
becom
associ
nuclear
bodi
nb
compon
particular
daxx
chromatin
remodel
enzym
chre
process
would
lead
major
immediateearli
promot
miep
silenc
without
counteract
effect
protein
fact
caus
degrad
daxx
block
miep
silenc
thu
activ
mie
gene
express
express
mie
gene
act
repressor
promot
concert
histon
deacetylas
hdac
bind
cr
furthermor
act
transactiv
viral
cellular
promot
induc
viral
earli
e
gene
express
modul
cellcycl
progress
infect
cell
depict
also
viral
target
affect
fomivirsen
membran
suppos
dock
nuclear
pore
complex
releas
viral
genom
nucleu
event
player
involv
process
still
poorli
character
two
capsidassoci
tegument
protein
ie
recent
shown
play
role
facilit
nuclear
transloc
viral
genom
fact
found
interact
two
cellular
nucleoporin
pasdeloup
et
al
addit
proteolyt
cleavag
nuclear
membran
shown
requir
effici
releas
viral
dna
nucleu
jovasev
et
al
despit
import
postfus
process
viru
replic
antihcmv
drug
inhibit
either
transport
capsid
nuclear
transloc
viral
genom
develop
far
identif
viral
protein
involv
process
understand
proteinprotein
interact
necessari
postfus
event
hcmv
cycl
strongli
requir
inde
disrupt
proteinprotein
interact
could
lead
inhibit
viru
replic
thu
may
repres
novel
strategi
develop
new
antihcmv
drug
approach
alreadi
success
appli
interact
herpesviru
protein
liuzzi
et
al
marcello
et
al
loregian
et
al
loregian
et
al
loregian
et
al
pilger
et
al
loregian
loregian
coen
nuclear
transloc
hcmv
genom
suffici
induc
onset
lytic
replic
fact
compel
experiment
evid
tegument
protein
local
nucleu
hcmvinfect
cell
effici
promot
viral
ie
gene
express
penkert
kalejta
entri
nucleu
hcmv
genom
attack
compon
intrins
cellular
antivir
defens
order
reach
viral
genom
silenc
effector
antivir
defens
primarili
chromatin
remodel
enzym
woodhal
et
al
cuevasbennett
shenk
nitzsch
et
al
protein
gener
found
constitu
nuclear
bodi
thank
activ
protein
particular
activ
transcript
corepressor
daxx
immedi
entri
incom
hcmv
genom
could
assimil
transcript
inact
heterochromatin
howev
protein
counteract
daxxmedi
major
immediateearli
promot
miep
repress
first
displac
daxx
corepressor
atrx
lukashchuk
et
al
induc
sumoyl
hwang
kalejta
eventu
target
proteasom
degrad
via
ubiquitinindepend
pathway
hwang
kalejta
mechan
therefor
abl
effici
contrast
inhibit
ie
gene
express
mediat
daxx
protein
also
target
rb
famili
member
degrad
thu
contribut
g
g
progress
virusinfect
cell
kalejta
shenk
mie
region
hcmv
genom
repres
one
complex
dna
sequenc
ever
studi
biolog
consist
mie
locu
encod
protein
express
regul
upstream
rightward
locat
enhancercontain
promot
ie
miep
rel
transcript
start
site
nucleotid
miep
span
base
enhanc
extend
base
enhanc
turn
divid
two
portion
proxim
enhanc
base
base
distal
enhanc
base
base
addit
uniqu
region
locat
base
two
compon
mie
enhanc
equival
fact
delet
distal
portion
enhanc
toler
high
moi
recombin
virus
lack
region
still
replic
albeit
slowli
show
smallplaqu
phenotyp
meier
pruessner
meier
et
al
contrast
delet
proxim
enhanc
result
nonviabl
virus
indic
region
absolut
requir
viru
replic
isomura
et
al
like
eukaryot
enhanc
mie
enhanc
hcmv
contain
high
number
repeat
cisact
bind
site
cellular
transcript
factor
tf
bound
attract
rna
polymeras
ii
compon
basal
transcript
machineri
permit
mie
gene
express
number
distribut
bind
site
vari
cmv
thu
reflect
possibl
exampl
adapt
throughout
coevolut
differ
host
reach
effici
viral
replic
review
see
keep
hypothesi
enhanc
murin
cmv
hcmv
interchang
isomura
stinski
hcmv
mie
enhanc
contain
tf
bind
site
common
cmv
eg
site
crebatf
hunninghak
et
al
liu
stinski
keller
et
al
well
bind
site
uniqu
hcmv
eg
site
retino
acid
receptor
serum
respons
factor
crebind
protein
site
angulo
ghazal
netterwald
et
al
howev
minim
enhanc
sequenc
effici
mie
gene
express
identifi
two
bind
site
gc
box
locat
base
base
observ
mutat
site
impair
mie
gene
transcript
isomura
et
al
mie
enhanc
hcmv
flank
two
diverg
viral
promot
ie
miep
discuss
gene
promot
uniqu
region
miep
act
like
insul
element
sinc
contain
bind
site
cellular
repressor
chao
et
al
lashmit
et
al
provid
neg
regul
promot
thu
block
influenc
mie
enhanc
transcript
also
mie
enhanc
subject
neg
regul
lead
repress
mie
gene
express
could
option
therapeut
point
view
fact
mie
region
hcmv
key
role
viru
reactiv
latenc
note
fact
ie
protein
express
nonpermiss
cell
latenc
reflect
role
acut
infect
well
reactiv
miep
region
span
base
contain
tata
box
cisrepress
sequenc
cr
locat
tata
box
transcript
start
site
initi
sequenc
macia
et
al
isomura
et
al
tata
box
serv
recognit
site
basal
transcript
machineri
assembl
sinc
basal
tf
recruit
promot
tata
boxbind
protein
tbp
interact
tf
ultim
promot
bind
rna
polymeras
ii
miep
hcmv
requir
promot
enhanc
effici
induc
mie
gene
transcript
enhancerless
recombin
hcmv
fact
abl
replic
isomura
et
al
also
cr
essenti
viru
replic
sinc
introduct
singl
point
mutat
cr
abrog
abil
recombin
viru
replic
pivot
role
play
miep
function
mie
gene
express
progress
product
infect
make
attract
target
novel
antivir
strategi
proofofprincipl
feasibl
approach
provid
sole
approv
antihcmv
drug
block
mie
gene
express
ie
fomivirsen
fomivirsen
isi
fig
market
novarti
ophtalm
antisens
odn
compos
phosphorothioatelink
nucleotid
identifi
screen
oligonucleotid
complementari
mrna
hcmv
mie
transcript
unit
azad
et
al
odn
abl
hybrid
mrna
thu
block
express
protein
initi
suppos
uniqu
mechan
antivir
action
fomivirsen
howev
sequenceunrel
effect
express
viral
gene
eg
report
azad
et
al
furthermor
fomivirsenresist
viru
mutat
gene
region
complementari
fomivirsen
detect
mulamba
et
al
therefor
besid
express
viral
function
might
affect
antivir
compound
adsorpt
entri
target
antivir
odn
shogan
et
al
luganini
et
al
approv
food
drug
administr
ophtalm
use
us
recommend
treatment
hcmvinduc
retin
aid
patient
withdrawn
european
market
commerci
reason
howev
remain
still
avail
european
patient
need
typic
administ
intravitr
inject
ml
two
dose
everi
two
week
recommend
patient
treat
cdv
may
increas
one
fomivirsen
typic
side
effect
ie
eye
inflamm
addit
ocular
system
sideeffect
report
fomivirsen
restrict
use
topic
administr
gener
antisens
odn
smallinterf
rna
sirna
repres
promis
class
antivir
agent
howev
suffer
sever
drawback
need
repeat
administr
poor
bioavail
low
stabil
fluid
ineffici
uptak
thu
limit
clinic
applic
review
see
fattal
bochot
reason
past
year
mani
effort
spent
extend
use
antisens
odn
sirna
system
drug
improv
pharmacokinet
cell
uptak
exploit
nanoparticul
deliveri
system
approach
includ
associ
cation
polym
polymer
nanocapsul
fattal
bochot
de
martimprey
et
al
exampl
success
applic
strategi
report
use
albumin
nanoparticl
combin
deliveri
gcv
phosphodiest
analog
fomivirsen
significatli
improv
effect
drug
irach
et
al
addit
fomivirsen
seri
compound
report
exert
repress
effect
hcmv
miep
activ
inhibit
mie
gene
express
tabl
howev
mani
exact
mechan
action
remain
yet
elucid
exampl
known
trichostatin
inhibitor
histon
deacetylas
hdac
trigger
miep
reactiv
ferguson
et
al
therefor
one
may
specul
inhibitor
histon
acetylas
histon
methyltransferas
could
exert
antihcmv
activ
silenc
miep
furthermor
pharmacolog
inhibit
cellular
signal
pathway
import
miep
activ
result
impair
viru
replic
johnson
et
al
context
compel
evid
drug
abl
perturb
cellular
signal
pathway
activ
also
signific
impact
miep
activ
protein
belong
class
cellular
tyrosin
kinas
activ
differ
mitogen
stimuli
activ
trigger
phosphoryl
cascad
togeth
cellular
kinas
includ
akt
infect
hcmv
strongli
upregul
signal
pathway
johnson
et
al
activ
akt
lead
eventu
activ
transcript
factor
import
induc
mie
gene
express
line
inhibitor
wortmannin
fig
report
inhibit
mie
gene
express
viral
dna
synthesi
prevent
activ
possibl
phosphoryl
cellular
protein
requir
effici
viru
replic
also
inhibitor
kinas
act
upstream
downstream
cell
signal
report
antihcmv
activ
exampl
worthi
note
artesun
fig
compound
initi
identifi
antimalaria
agent
current
use
treatment
plasmodium
spp
infect
rosenth
later
artesun
discov
inhibit
hcmvinduc
transactiv
activ
necessari
activ
miep
efferth
et
al
studi
elucid
mechan
antihcmv
activ
artesun
indic
block
activ
two
effector
pathway
ie
akt
work
need
fulli
approv
antihcmv
drug
azad
et
al
transactiv
activ
block
el
protein
express
preclin
loregian
et
al
understand
antivir
mechan
drug
could
repres
altern
option
treatment
hcmv
infect
fact
artesun
shown
good
bioavail
profil
lack
signific
toxic
clinic
antimalaria
studi
hien
et
al
hien
et
al
nosten
recent
report
fig
multitarget
tyrosin
kinas
inhibitor
use
anticanc
treatment
also
block
hcmv
replic
nontox
clinic
relev
concentr
micha
et
al
inhibit
miep
activ
mie
gene
express
panel
differ
cell
line
exact
mechan
antihcmv
activ
sorafenib
yet
establish
nevertheless
indic
suggest
inhibit
cellular
kinas
raf
could
involv
although
role
raf
mie
gene
express
describ
previous
micha
et
al
raf
cell
signal
effector
act
mitogenactiv
kinas
mek
erkmapk
also
involv
activ
pathway
wellbrock
et
al
studi
necessari
establish
whether
sorafenib
might
repres
novel
antihcmv
drug
particular
cancer
patient
risk
hcmv
reactiv
prospect
micha
et
al
final
also
inhibitor
cellular
process
directli
involv
viru
replic
shown
exert
antihcmv
activ
perturb
cellular
function
necessari
trigger
mie
gene
express
case
geldanamycin
fig
inhibitor
interfer
hcmv
replic
basha
et
al
inhibit
molecular
chaperon
lead
inactiv
client
protein
includ
akt
kinas
involv
signal
anoth
exampl
repres
proteasom
inhibitor
particular
fig
shown
abil
block
hcmv
replic
prosch
et
al
transcript
factor
one
import
activ
miep
found
inact
cytoplasmat
complex
repressor
activ
divers
kinas
respons
extracellular
stimuli
lead
phosphoryl
latter
proteasom
degrad
via
ubiquitindepend
pathway
result
activ
therefor
antihcmv
activ
report
might
mainli
due
cytosol
accumul
caus
lack
proteasom
degrad
fail
releas
block
nuclear
transloc
abrog
ie
gene
express
proteasom
inhibitor
howev
demonstr
also
inhibitori
effect
hcmv
process
kaspari
et
al
summari
varieti
compound
report
antihcmv
activ
stage
act
exert
primari
inhibitori
activ
cellular
target
fact
kept
mind
none
compound
first
discov
antihcmv
agent
neither
specif
design
inhibit
particular
viral
function
case
fomivirsen
furthermor
although
compound
report
tabl
inhibit
hcmv
replic
concentr
clinic
relev
none
select
index
compar
gcv
perturb
cellular
pathway
andor
function
might
feasibl
strategi
sinc
nonspecif
advers
effect
exclud
therefor
accur
studi
need
establish
whether
inhibitor
could
use
clinic
antihcmv
set
abund
hcmv
ie
protein
origin
loci
control
mie
enhancerpromot
mie
protein
detect
h
pi
ishov
et
al
call
two
protein
product
altern
splice
event
lead
differ
mrna
consequ
first
two
exon
common
diverg
cterminu
end
exon
aa
sequenc
exon
gene
product
origin
locu
ie
protein
shorter
form
dispens
hcmv
replic
report
play
role
l
gene
express
miep
repress
white
et
al
essenti
viru
replic
although
greatli
augment
effici
hcmv
infect
act
transactiv
well
interact
cellular
protein
thu
cooper
creat
favor
environ
viru
replic
low
moi
lack
affect
viral
replic
howev
high
moi
absenc
appear
compens
activ
viral
andor
cellular
protein
gawn
greav
multitask
protein
essenti
viru
replic
fact
recombin
virus
carri
delet
exon
abl
complet
replic
cycl
lack
e
gene
express
marchini
et
al
transactiv
properti
e
gene
complement
activ
either
viral
cellular
protein
fact
function
indispens
viru
growth
make
appeal
target
novel
antivir
strategi
howev
date
drug
affect
function
licens
discuss
main
role
fulfil
render
infect
host
cell
suitabl
environ
hcmv
replic
could
target
antivir
compound
addit
sever
ancillari
ie
protein
exist
colbergpoley
castillo
kowalik
mercorelli
et
al
encod
hcmv
loci
howev
although
protein
known
play
import
role
hcmv
replic
thu
could
potenti
antivir
target
antivir
agent
specif
direct
one
protein
ie
phosphorothio
oligonucleotidegem
complementari
intronexon
boundari
ie
gene
develop
sinc
initi
report
dvorchik
marqui
compound
specif
direct
viral
target
describ
last
decad
abil
repress
promot
essenti
viru
replic
form
homodim
bind
directli
dna
sequenc
miep
ie
cr
locat
tata
box
transcript
start
site
regulatori
element
consist
sequenc
gc
dinucleotid
flank
two
rich
region
wahe
et
al
bind
cr
physic
block
recruit
rna
polymeras
ii
thu
prevent
assembl
preiniti
complex
subsequ
mie
gene
express
mutat
cr
abl
impair
dnaprotein
interact
lethal
effect
viru
replic
petrik
et
al
isomura
et
al
howev
seem
cr
might
dual
role
hcmv
replic
fact
report
first
phase
hcmv
replic
unknown
cellular
protein
kda
interact
cr
interact
result
increas
mie
gene
express
progress
viru
replic
abundantli
express
becom
abl
compet
cellular
protein
cr
bind
thu
exert
repress
effect
promot
furthermor
abl
interact
repress
chromatin
remodel
enzym
park
et
al
recruit
protein
caus
deacetyl
histon
miep
modif
chromatin
statu
promot
lead
silenc
mie
gene
one
strike
featur
abil
function
transactiv
gene
express
repressor
major
transactiv
viral
e
gene
protein
enhanc
activ
nevel
et
al
transactiv
properti
mainli
reli
proteinprotein
interact
fact
interact
sever
compon
basal
transcript
machineri
includ
tbp
tfiib
caswel
et
al
show
taflik
function
lukac
et
al
lukac
et
al
furthermor
attract
histon
acetylas
permit
activ
viral
e
promot
bryant
et
al
nevel
et
al
howev
also
evid
direct
bind
dna
sequenc
e
promot
requir
effici
promot
activ
schwartz
et
al
sculli
et
al
transactiv
function
essenti
progress
hcmv
lytic
replic
cycl
sinc
point
mutat
affect
abil
either
bind
e
promot
petrik
et
al
interact
basal
transcript
factor
harri
et
al
abrog
hcmv
replic
furthermor
although
rna
polymeras
ii
tbp
recruit
viral
e
promot
absenc
latter
remain
essenti
achiev
e
gene
express
petrik
et
al
also
act
repressor
key
cellular
regul
eg
tumor
suppressor
rb
hagemei
et
al
interact
rb
induc
activ
gene
whose
product
respons
g
progress
hcmvinfect
cell
thu
provid
way
bypass
cellular
quiescenc
also
immunomodul
respons
block
proinflammatori
signal
necessari
surviv
hcmvinfect
cell
mechan
involv
nfkb
inhibit
taylor
bresnahan
fact
act
nfkb
antagonist
block
dnabind
activ
henc
attenu
express
nfkbdepend
proinflammatori
chemokin
taylor
bresnahan
pool
et
al
past
year
mani
effort
aim
identifi
whether
transactiv
domain
could
separ
domain
respons
autoregul
definit
answer
found
yet
core
domain
initi
identifi
amino
acid
appar
requir
function
asmar
et
al
recent
studi
character
effect
two
doubl
mutat
ie
shed
light
aspect
petrik
et
al
fact
author
show
mutant
still
abl
autoregul
miep
even
though
compet
transactiv
suggest
like
use
two
independ
mechan
cr
bind
activ
viral
e
promot
recent
analysi
effect
point
mutat
amino
acid
perform
assess
impact
singl
aa
chang
transactiv
activ
vitro
context
viral
replic
harri
et
al
studi
evidenc
residu
essenti
promot
activ
contrast
mutat
either
inhibit
promot
transactiv
thu
possibl
might
use
distinct
mechan
activ
differ
respons
promot
suggest
nevertheless
identif
residu
essenti
autoregulatorytransactiv
function
merit
investig
comprehens
molecular
level
mechan
action
protein
could
provid
rout
develop
inhibitor
number
compound
report
block
viral
e
l
gene
express
ie
gene
express
tabl
mechan
involv
inhibit
function
suggest
exampl
repres
genistein
ever
et
al
berberin
hayashi
et
al
addit
inhibitor
cellular
kinas
mek
mapk
shown
suppress
phosphoryl
result
inhibit
hcmv
delay
e
gene
express
viral
dna
replic
johnson
et
al
chen
stinski
sinc
phosphoryl
level
correl
transactiv
activ
barrasa
et
al
inhibit
posttransl
modif
investig
potenti
antivir
target
recent
class
compound
name
emerg
novel
antivir
compound
act
block
viral
transactiv
function
parolin
et
al
recent
fig
potent
select
inhibit
hcmv
replic
ec
identifi
mercorelli
et
al
remark
featur
specif
inhibit
hcmv
replic
exhibit
select
index
favor
gcv
signific
activ
human
herpesvirus
mercorelli
et
al
importantli
also
potent
activ
clinic
strain
hcmv
recov
infect
patient
well
viru
strain
resist
drug
current
use
antihcmv
therapi
eg
gcv
fo
cdv
reason
consid
promis
lead
develop
novel
antihcmv
drug
studi
perform
elucid
mode
action
demonstr
act
mechan
differ
licens
antihcmv
drug
loregian
et
al
fact
inhibit
either
hcmv
dna
polymeras
activ
ie
gene
express
interfer
transactiv
activ
protein
exploit
cellbas
assay
develop
identifi
inhibitor
luganini
et
al
demonstr
abl
inhibit
transactiv
viral
e
gene
thu
block
e
l
gene
express
loregian
et
al
importantli
act
synergist
gcv
hcmv
replic
cytotox
effect
two
compound
combin
addit
loregian
et
al
find
open
possibl
combin
therapi
similar
synergist
effect
vivo
could
provid
mean
treat
hcmv
infect
reduc
drug
toxic
outcom
drugresist
mutant
first
antivir
compound
report
directli
block
activ
essenti
protein
howev
take
advantag
cellbas
assay
develop
luganini
colleagu
luganini
et
al
inhibitor
could
identifi
deeper
investig
need
elucid
mechan
inhibit
transactiv
activ
molecular
level
verifi
whether
antivir
activ
functionsact
might
involv
whose
inhibit
could
contribut
block
viru
replic
cell
hcmv
infect
still
associ
sever
morbid
mortal
especi
vulner
immunocompromis
patient
despit
avail
five
drug
current
licens
antivir
therapi
thu
new
antihcmv
agent
urgent
need
inhibit
hcmv
entri
express
ie
gene
repres
emerg
field
studi
could
provid
efficaci
strategi
reduct
ablat
product
infect
inde
success
develop
hiv
entri
inhibitor
kuritzk
joli
et
al
provid
impetu
design
antivir
compound
target
one
essenti
step
occur
earli
viru
replic
cycl
date
number
promis
novel
compound
target
initi
phase
hcmv
replic
differ
stage
develop
thu
strong
hope
least
compound
describ
deriv
reach
marketplac
help
improv
treatment
option
area
high
unmet
medic
need
circumv
toxic
bioavail
resist
efficaci
issu
associ
current
antihcmv
drug
moreov
avail
compound
target
viral
event
besid
genom
replic
could
allow
design
activ
therapeut
protocol
base
combin
use
multipl
antihcmv
drug
like
highli
activ
antiretrovir
therapi
chang
live
hivinfect
patient
research
effort
dissect
molecular
interact
mechan
involv
first
event
hcmv
life
cycl
clearli
necessari
identifi
novel
drug
target
develop
new
inhibitor
target
